Molecular Internal Medicine

Renal Medicine

Endothelial factors in the pathogenesis and treatment of chronic kidney disease
G.P. Rossi, T. M. Secchia, M. Barton. A.H. Danser, P. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito, N. Hasebe, D.J. Webb.
European Society of Hypertension Scientific Newsletter 19 (67), 1-2, 2018

GPER is required for age-dependent albuminuria and glomerulosclerosis: evidence for its role in podocyte injury and mesangial Nox1 regulation
M.R. Meyer, D. Daniel, C.D. Woods, G. Sharma, N.C. Fredette, K. Amann, M. Barton, E.R. Prossnitz
Hypertension 72 (suppl).:P261, 2018


GPER blockers as Nox downregulators: a new drug class to target chronic non-communicable diseases
M.R. Meyer, M. Barton

J Steroid Biochem Mol Biol 176, 82-87, 2018

Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: role in disease conditions. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 462-471, 2018

Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: general mechanisms. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 451-461, 2018


GPER mediates functional endothelial aging in renal arteries
M.R. Meyer, T. Rosemann, M. Barton, E.R. Prossnitz.
Pharmacology 100, 188-193, 2017

Estrogen signaling in the adrenal cortex: implications for blood pressure sex differences
B. Carrocia, T.M. Seccia, M. Barton, G.P. Rossi
Hypertension 68, 840-848, 2016

Endothelin and the glomerulus in chronic kidney disease
M. Barton, A. Sorokin
Semin Nephrol 35, 156-167, 2015

Endothelin and endothelin antagonists in chronic kidney disease
D.E. Kohan, M. Barton
Kidney Int 86, 896-904, 2014

Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?
D.E. Kohan, J.G. Cleland, L.J. Rubin, D. Theodorescu, M. Barton

Life Sci 91, 528-539, 2012

Endothelin and the podocyte
M. Barton, P.L. Tharaux

Clin Kidney J 5, 17-27, 2012

Endothelin receptor antagonists in cardiovascular medicine: Challenges and opportunities
M. Barton
In: Translational Vascular Medicine (D. Abraham, Ed) Springer London, 231-259, 2012

Endothelin antagonists in clinical trials: Lessons learned
M. Barton, D.E. Kohan

Contrib Nephrol 172, 255-260, 2011

Endothelin and podocyte injury in chronic kidney disease
C. Fligny, M. Barton, P.L. Tharaux

Contrib Nephrol 172, 120-138, 2011

Endothelin antagonism and reversal of proteinuric renal disease in humans
M. Barton

Contrib Nephrol 172, 210-222, 2011

Anti-inflammatory effects of endothelin receptor antagonists and their importance for treating human disease
M. Barton, P.C. Nett, K. Amann, M.M. Teixeira
Front Cardiovasc Drug Discov 1, 236-258, 2010

Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans
M. Barton
Biochim Biophys Acta 1802, 1203-1213, 2010

Reversal of proteinuric renal disease and the emerging role of endothelin
M. Barton
Nature Clin Pract Nephrol 4, 490-498, 2008

Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats
T. Traupe, J. Ortmann, E. Haas, K. Münter, N. Parekh, R. Hofmann-Lehmann, K. Baumann, M. Barton
J Cardiovasc Pharmacol 47, 456-462, 2006

Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes
J. Ortmann, P.C. Nett, J. Celeiro, R. Hofmann-Lehmann, L. Tornillo, L.M. Terraciano, M. Barton
Exp Biol Med (Maywood) 231, 1030-1033, 2006

Anatomically distinct activation of endothelin-3 and the L-arginine/nitric oxide pathway in the kidney with advanced aging
T. Lattmann, S. Shaw, K. Münter, W. Vetter, M. Barton
Biochem Biophys Res Commun 327, 234-241, 2005

Ageing as a determinant of renal and vascular disease: role of endothelial factors
M. Barton
Nephrol Dial Transplant 20, 485-490, 2005

Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition
J. Ortmann, K. Amann, R.P. Brandes, M. Kretzler, K. Münter, N. Parekh, T. Traupe, M. Lange, T. Lattmann, M. Barton
Hypertension 44, 974-981, 2004

Inverse regulation of endothelin-1 and nitric oxide metabolites in tissue with aging: implications
for the age-dependent increase of cardiorenal disease

M. Barton, T. Lattmann, L.V. d'Uscio, T.F. Luscher, S. Shaw
J Cardiovasc Pharmacol 36 (Suppl.1), S153-S156, 2000

Endothelin regulates angiotensin-converting enzyme in the mouse kidney
M. Barton, R. Carmona, J.E. Krieger, W. Göettsch, H. Morawietz, L.V. d'Uscio, T. Lattmann, T.F. Luscher, S. Shaw
J Cardiovasc Pharmacol 36 (Suppl.1), S244-S247, 2000

Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms
of renal artery dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis

M. Barton, I. Vos, S. Shaw, P. Boer, L.V. d'Uscio, H.-J. Gröne, T.J. Rabelink, T. Lattmann, P. Moreau, T.F. Luscher
J Am Soc Nephrol 11, 835-846, 2000

Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo.
Evidence for a regulatory role of endothelin

M. Barton, R. Carmona, H. Morawietz, L.V. d'Uscio, W. Goettsch, H. Hillen, C.C. Haudenschild, J.E. Krieger,
K. Münter, T. Lattmann, T.F. Luscher, S. Shaw
Hypertension 35, 329-336, 2000

Endothelin antagonists for hypertension and renal disease
M. Barton, T.F. Luscher
Curr Opin Nephrol Hypertens 8, 549-556, 1999

Endothelial dysfunction in acute renal faiulre: role of circulating and tissue endothelin-1
F. Ruschitzka, S. Shaw, D. Gygi, G. Noll, M. Barton, T.F. Luscher
J Am Soc Nephrol 10, 953-962, 1999


Salt Wars
M. Barton, T.F. Luscher, T.J. Rabelink
Science 281, 1961, 1998

Endothelial vasoconstrictor prostanoids, vascular reactivity, and acute renal failure
F. Ruschitzka, S. Shaw, G. Noll, M. Barton, E. Schulz, G.A. Müller, T.F. Luscher
Kidney Int 67, S199-S201, 1998

Differential modulation of the renal myocardial endothelin system by angiotensin II in vivo: effects of chronic selective ETA receptor blockade
M. Barton, S. Shaw, L. V. d'Uscio, P. Moreau, T.F. Luscher
J Cardiovasc Pharmacol 31 (Suppl 1), S265-S268, 1998

Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation
M. Barton, S. Shaw, L.V. d`Uscio, P. Moreau, T.F. Luscher
Biochem Biophys Res Commun 238, 861-865, 1997